Arvinas to Participate in Upcoming Investor Conferences
February 06, 2023 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Changes to its Board of Directors
December 16, 2022 09:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
November 22, 2022 07:12 ET
|
Arvinas Inc.
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7...
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 07:00 ET
|
Arvinas Inc.
– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical trials and initiating enrollment...
Arvinas to Present at Upcoming Conferences
November 01, 2022 16:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
October 27, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation (TPD),...
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
October 03, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Gives Back to Local Greater New Haven Community
September 30, 2022 09:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Bank of America Securities Precision Oncology Conference
September 26, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...